NAD+ — Coenzyme, Research and Hype

What NAD+ is and why it matters so much

NAD+ is what is known as a coenzyme — a helper molecule without which many central metabolic reactions simply cannot proceed. Put simply, it is a shuttle molecule that transports electrons and thereby helps convert food into energy (ATP). In doing so it switches between two states: NAD+ (oxidized) and NADH (reduced). Beyond that, NAD+ serves as raw material for enzymes involved in repairing and regulating the cell, including the much-discussed sirtuins and the DNA-repair enzymes (PARPs).

The body produces NAD+ itself — among other things from building blocks of the vitamin B3 family (niacin, nicotinamide) as well as from the precursors NR and NMN. Observational data suggest that NAD+ levels decline with age in many tissues. This is precisely where the longevity idea takes hold: if less NAD+ goes hand in hand with aging, then topping it up might perhaps help. The distinction between correlation and cause is important — a falling level is not automatically the cause of aging, but could equally be an accompanying phenomenon.

• NAD+ is a coenzyme in almost every cell, central to producing energy
• It also supplies raw material for repair and regulatory enzymes (sirtuins, PARPs)
• Levels fall with age — whether as cause or consequence is unresolved
• NAD+ is usually taken not directly, but as a precursor (NR, NMN)

The precursors NR and NMN: the route into the blood

NAD+ itself cannot simply be swallowed as a pill — the large molecule is broken down in the digestive tract. That is why research works with smaller precursors that the body can absorb and convert internally into NAD+. The two best known are NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide). Chemically, both belong to the extended vitamin B3 family.

That these precursors can raise the measurable NAD+ level in the blood is in fact well documented. In a randomized, placebo-controlled study in healthy middle-aged and older adults, NR increased the NAD+ content in certain blood cells by around 60 percent compared with placebo. For NMN, a small controlled study in healthy subjects likewise showed a significant rise in whole-blood NAD+ levels. So far, so clear: the biochemistry works — the tank can be refilled.

• Swallowing NAD+ directly barely works — it gets digested
• NR and NMN are smaller precursors the body converts into NAD+
• Both demonstrably raise blood NAD+ levels
• The biomarker effect (more NAD+ in the blood) is solidly documented

What the human evidence really shows — and what it doesn't

This is where the honest appraisal begins. That NAD+ rises in the blood is a biomarker — a measured quantity, not a health benefit in itself. The decisive question is: does it make you live longer, healthier or fitter? That is precisely what has not been convincingly shown in humans so far.

In the NR study mentioned, NAD+ levels did rise markedly, yet the clinical measures yielded meager results: no demonstrated improvement in endurance, mobility or metabolic values. There were merely statistically unsecured tendencies in blood pressure and arterial stiffness, which the authors explicitly described only as hypotheses for larger future studies. The NMN study, in turn, was small with around 30 participants, examined primarily safety and blood NAD+ levels, and measured neither effects in other tissues nor hard clinical endpoints.

An important point about the so-called hype: many of the spectacular results — animals living longer, rejuvenating blood vessels, more endurance — come from experiments in mice and cell cultures. Such findings are valuable as a signal, but as is well known they cannot be transferred one-to-one to humans. Statements such as "NMN rejuvenates" or "NAD+ turns back the biological clock" must therefore be classed as claims, not as documented facts.

• More NAD+ in the blood is a biomarker, not a proven benefit
• Clinical improvements (fitness, metabolism) are not convincingly documented in humans
• Many impressive findings come from mouse and cell studies
• Human studies are often small, short and designed around safety/biomarkers
• "Anti-aging" promises are claims, not proven facts

Regulatory status: a shifting, inconsistent picture

NAD+ precursors are not approved medicines with a proven anti-aging benefit; rather, they sit in the realm of dietary supplements and research — and the legal framework differs considerably by region and substance.

In the USA, NMN was contentious for a time: the FDA excluded it from the dietary-supplement category in 2022 because it had previously been investigated as a drug. The agency revised this position in September 2025, again declaring NMN permissible as an ingredient in dietary supplements. NR is established in the USA as a dietary-supplement ingredient.

In the EU, novel-food law applies to both. NR chloride is already approved as a novel food. NMN, by contrast, is still in the assessment process: the European authority EFSA issued a positive safety assessment for an NMN product in 2026 — a step toward approval, but not yet a general market authorization for all manufacturers. The bottom line: the status differs by country and substance, is in flux, and is by no means a seal of quality for a health benefit. A safety assessment says something about tolerability, not about efficacy.

• Not an approved medicine with a proven anti-aging benefit
• USA: NMN excluded in 2022, re-approved as a supplement ingredient in September 2025
• EU: NR chloride approved as a novel food, NMN still in the assessment process
• A safety assessment proves tolerability, not efficacy

Risks, limits and a sober appraisal of the hype

In the available short-term studies in healthy adults, NR and NMN were largely well tolerated, with no serious side effects. That sounds reassuring, but has clear limits: the studies were small, short (often a few weeks) and conducted in selected, healthy individuals. They say little about long-term safety with years of intake, about interactions with medications, or about use in people with pre-existing conditions. In particular, the theoretical concern of whether a permanently elevated NAD+ metabolism could have unfavorable effects on cell growth has simply not been sufficiently investigated in humans.

On top of this comes the usual gray-market problem: products sold as "research" goods or without strict controls can deviate in content and purity from what is declared. A reputable product says nothing about the advertised anti-aging effect — at best it says something about the quality of the ingredient.

Conclusion for context: NAD+ is fascinating, genuinely important biochemistry, and precursors raise the blood level measurably. The leap from there to "rejuvenated," "lives longer" or "turns back aging" is, however, not documented in humans and belongs to marketing hype, not to established evidence. Anyone toying with the idea of using such products would do well to discuss it with a physician — especially in the case of pre-existing conditions, medication use, pregnancy or breastfeeding.

• Short-term tolerability in healthy people is mostly good, but long-term safety is open
• Little data on interactions and use in people with pre-existing conditions
• Gray-market goods can deviate in content and purity
• "Rejuvenation" and "longer life" are not documented in humans
• Seek medical advice with pre-existing conditions, medications, pregnancy/breastfeeding